Physician profile
Stephen D Levine
NPI 1477526598
$1,356.75
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $193 · 2021: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $249.78 | 2019 | |
| Abbvie INC. | $227.03 | 2019-2021 | |
| Gilead Sciences, INC. | $211.16 | 2019-2020 | |
| Advanced Respiratory, INC | $197.43 | 2019-2020 | |
| Electromed, INC. | $176.71 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $155.87 | 2019-2020 | |
| Genentech USA, INC. | $105.07 | 2019 | |
| Philips North America LLC | $19.60 | 2019 | |
| Pfizer INC. | $14.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.